MET: roles in epithelial-mesenchymal transition and cancer stemness

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• The MET pathway, when deregulated, drives key cancer processes including proliferation, invasion, and angiogenesis.
• Aberrant MET signaling is implicated in malignant transformation, cell motility, and survival under hypoxic conditions.

Purpose of the Study:

• To review the multifaceted roles of MET signaling in various cancers.
• To focus on the involvement of MET in epithelial-mesenchymal transition (EMT) and cancer stemness.
• To provide an update on MET-targeting agents and discuss therapeutic challenges.

Main Methods:

• Literature review synthesizing current research on MET signaling in cancer.
• Analysis of the connection between MET pathway activation and cancer progression hallmarks.
• Review of existing and emerging MET-targeting therapeutic strategies.

Main Results:

• Deregulated MET signaling promotes critical cancer phenotypes such as uncontrolled proliferation, enhanced cell migration, and angiogenesis.
• MET pathway plays a significant role in driving epithelial-mesenchymal transition (EMT) and maintaining cancer stem cell populations.
• Several MET-targeting agents are under investigation, showing promise but facing challenges in clinical development.

Conclusions:

• A comprehensive understanding of MET signaling is crucial for advancing cancer therapy.
• Targeting the MET pathway holds potential for treating a range of cancers, particularly those driven by MET dysregulation.
• Overcoming challenges in MET-targeted therapy development is essential for improving patient outcomes.